Every six months or so, the pressure around compounded GLP-1 medications seems to ratchet up another notch. Sometimes it comes through FDA guidance, sometimes through shortage decisions or public statements, and this week we are seeing another escalation yet. With each passing year, the landscape feels more difficult to make clean sense of.

FDA has issue…